Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9199829 | 0.84 | SIGMAR1 (0.40) | SIGMAR1CYP2D6KIF11HTR2ACHRNB2 | |
| Hydrochloric Acid SCHEMBL3672966 | 0.82 | SIGMAR1 (0.49) | SIGMAR1CYP2D6KIF11 | |
| SCHEMBL10731199 | 0.80 | SIGMAR1 (0.50) | SIGMAR1CYP2D6HTR2A | |
| SCHEMBL10731211 | 0.80 | SIGMAR1 (0.50) | SIGMAR1CYP2D6HTR2A | |
| SCHEMBL10727791 | 0.80 | SIGMAR1 (0.62) | SIGMAR1CYP2D6 | |
| SCHEMBL10727786 | 0.80 | SIGMAR1 (0.62) | SIGMAR1CYP2D6 | |
| SCHEMBL9673634 | 0.80 | CHRNB2 (0.53) | SIGMAR1CYP2D6CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3594198 | 0.80 | CHRNB2 (0.53) | SIGMAR1CYP2D6CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9673637 | 0.80 | CHRNB2 (0.53) | SIGMAR1CYP2D6CHRNB2CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL7965310 | 0.77 | CHRNB2 (0.46) | SIGMAR1CYP2D6CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549761-A4 | METHODS AND COMPOSITIONS FOR THE MODIFICATION OF NUCLEIC ACIDS | VI TECHNOLOGIES INC (US) | 2006-02-15 | — | — | EP | disclosed |
| EP-1549761-A1 | METHODS AND COMPOSITIONS FOR THE MODIFICATION OF NUCLEIC ACIDS | V.I. Technologies, Inc. (US) | 2005-07-06 | — | — | EP | disclosed |
| WO-2005042060-A2 | METHOD AND COMPOSITION COMPRISING PYRUVATE, INOSINE, ADENINE, PHOSPHATE AND AN AZIRIDINO COMPOUND FOR TREATING A BIOLOGICAL SAMPLE | V.I. TECHNOLOGIES, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050074743-A1 | Method and composition for treating a biological sample | V.I. TECHNOLOGIES, INC. | 2005-04-07 | — | — | US | disclosed |
| WO-2005002570-A1 | USE OF AN AZIRIDINO COMPOUND TO SELECTIVELY INACTIVATE PARASITES IN BIOLOGICAL COMPOSITIONS | V.I. TECHNOLOGIES, INC. (US) | 2005-01-13 | — | — | WO | disclosed |
| EP-1451308-A4 | THERAPEUTIC USE OF AZIRIDINO COMPOUNDS | VI TECHNOLOGIES INC (US) | 2004-11-17 | — | — | EP | disclosed |
| EP-1451308-A2 | THERAPEUTIC USE OF AZIRIDINO COMPOUNDS | V.I. Technologies, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040053208-A1 | Methods to selectively inactivate parasites in biological compositions | V. I. TECHNOLOGIES, Inc. (US) | 2004-03-18 | — | — | US | disclosed |
| WO-2003093512-A1 | METHODS AND COMPOSITIONS FOR THE MODIFICATION OF NUCLEIC ACIDS | V.I. TECHNOLOGIES, INC. (US) | 2003-11-13 | — | — | WO | disclosed |
| WO-2003066806-A2 | THERAPEUTIC USE OF AZIRIDINO COMPOUNDS | V.I. TECHNOLOGIES, INC. (US) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050074743-A1 | Method and composition for treating a biological sample | APOB, MB, ALPP | SIGMAR1 4817/4885CYP2D6 1922/4885KIF11 3479/4885 |
| US-20040053208-A1 | Methods to selectively inactivate parasites in biological compositions | AZI2, MPO, GZMB | SIGMAR1 4093/4885CYP2D6 3299/4885KIF11 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.